Search the Newsreel

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise

NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary

NEKTAR THERAPEUTICS reported Q2 2026 results with revenue of $10.1 million and a net loss of $40.6 million, an improvement from the $41.6 million loss in the prior year. The diluted loss per share was $(1.23). The company highlighted advancements in its pipeline, including …

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics announced the initiation of its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis, with top-line data expected in mid-2028 and a potential BLA submission in 2029. The company also finalized plans for a registrational Phase III trial …

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds

Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Okta (OKTA) Stock Looks Pricey On Cash Flow And Earnings

Okta’s AI‑Native Identity Push And MCP Cost Controls Could Be A Game Changer For Okta (OKTA)

Earlier this week, Citizens JMP Securities upgraded Okta to "Market Outperform," highlighting the company's expanded AI-focused identity security capabilities, including its Permiso Security acquisition, new partnerships, and recently enhanced products geared toward securing AI agents. Okta also introduced identity-scoped Model Context Protocol tool lists …

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Massive Update for Okta Stock Investors

I have had Okta(NASDAQ: OKTA) stock ranked as a buy for several years. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total …

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

Okta (OKTA) Could Be 3% Above Fair Value Following The JMP Upgrade

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Okta (OKTA) moved into focus after Citizens JMP Securities upgraded the cybersecurity company to Market Outperform, citing its role in securing identity for …

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Citizens Just Upgraded OKTA Ahead of Upcoming Catalysts. How to View OKTA Stock Now.

The Wall Street sign is seen outside the New York Stock Exchange by hapabapa via iStock Okta (OKTA) stock has delivered one of the more striking moves in software this year. Its shares have climbed 93.8% over the past three months. That sharp re-rating …

Nektar earnings in focus as Phase 3 trial launch raises stakes

Nektar Therapeutics is preparing to report second-quarter results, with analysts anticipating a loss of $2.00 per share on revenues of $10.38 million. The report comes as the company launched two pivotal Phase 3 trials for its lead drug candidate, rezpegaldesleukin, drawing investor attention to …

Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up?

Nektar Therapeutics (NKTR) has experienced significant stock momentum, with year-to-date returns of 75.1% and a 1-year total shareholder return of 195.61%, despite a negative five-year record. The company's stock, currently at $76.03, is considered undervalued by one narrative, with a fair value of $153.25, …

Mukta Arts reports consolidated net loss of Rs 2.15 crore in the June 2026 quarter

Mukta Arts standalone net profit rises 92.11% in the June 2026 quarter

Okta (OKTA) Stock Falls Amid Market Uptick: What Investors Need to Know

Okta (OKTA) closed at $147.30 in the latest trading session, marking a -2.02% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.26%. At the same time, the Dow lost 0.04%, and the tech-heavy Nasdaq gained 0.54%. …

Dear Okta Stock Fans, Mark Your Calendars for August 26

An Okta sign on a corporate office_ Image by Sundry Photography via Shutterstock_ Okta (OKTA) investors have a key date to watch as the identity and access management company prepares to report its second-quarter fiscal 2027 financial results after the market close on Wednesday, …

Okta upgraded as AI security opportunity boosts outlook

Investing.com -- Cybersecurity firm Okta is well positioned to benefit from growing enterprise demand for identity controls as companies deploy artificial intelligence agents, Citizens JMP Securities said on Wednesday, upgrading the stock and raising its price target. The brokerage said identity has emerged as …

Could Okta’s (OKTA) Sales Execution Upside Reshape Confidence In Its Identity Security Strategy?

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Brokerages

Nektar Therapeutics (NASDAQ:NKTR) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $150.00. The company's shares opened at $75.50, and institutional investors own 75.88% of the stock. Insider selling has also been noted, with executives selling …

Krakatoa Resources Seeks ASX Quotation for 400 Million New Shares

Krakatoa Resources Expands Share Base with Major ASX Issuance

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

Kuehn Law is investigating Nektar Therapeutics (NASDAQ: NKTR) following a federal securities lawsuit alleging that the company misrepresented or failed to disclose issues with its REZOLVE-AA trial for its lead product candidate. The lawsuit claims that enrollment did not follow protocol standards, which was …